APC is altered in 3.96% of high-grade glioma, NOS patients [2].

APC is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains APC status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK6 is altered in 1.09% of high-grade glioma, NOS patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

CTDNEP1 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains CTDNEP1 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

CTNNB1 is altered in 0.99% of high-grade glioma, NOS patients [2].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

DDX3X is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

GLI2 is altered in 3.91% of high-grade glioma, NOS patients [2].

GLI2 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains GLI2 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is altered in 11.8% of high-grade glioma, NOS patients [2].

H3F3A is an inclusion eligibility criterion in 2 clinical trials for high-grade glioma, NOS, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and high-grade glioma, NOS as inclusion criteria, 2 are phase 1 (2 open) [3].

IDH1 is altered in 17.82% of high-grade glioma, NOS patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 is altered in 1.98% of high-grade glioma, NOS patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

KDM6A is altered in 2.17% of high-grade glioma, NOS patients [2].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2C is altered in 6.02% of high-grade glioma, NOS patients [2].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains KMT2C status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2D is altered in 5.43% of high-grade glioma, NOS patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP1B is altered in 2.52% of high-grade glioma, NOS patients [2].

LRP1B is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is altered in 1.09% of high-grade glioma, NOS patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is altered in 1.09% of high-grade glioma, NOS patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYC status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCL is altered in 0.54% of high-grade glioma, NOS patients [2].

MYCL is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYCL status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is altered in 4.35% of high-grade glioma, NOS patients [2].

MYCN is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

OTX2 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains OTX2 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D is altered in 4.14% of high-grade glioma, NOS patients [2].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

PTCH1 is altered in 3.26% of high-grade glioma, NOS patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is altered in 13.86% of high-grade glioma, NOS patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

PVT1 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains PVT1 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

RELA is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains RELA status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

SHH is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains SHH status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is altered in 4.35% of high-grade glioma, NOS patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

SMO is altered in 1.49% of high-grade glioma, NOS patients [2].

SMO is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains SMO status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

SNCAIP is altered in 3.7% of high-grade glioma, NOS patients [2].

SNCAIP is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains SNCAIP status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

SUFU is altered in 1.09% of high-grade glioma, NOS patients [2].

SUFU is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains SUFU status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

TERT is altered in 2.75% of high-grade glioma, NOS patients [2].

TERT is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains TERT status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 38.12% of high-grade glioma, NOS patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

YAP1 is altered in 1.1% of high-grade glioma, NOS patients [2].

YAP1 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains YAP1 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].

ZMYM3 is an inclusion eligibility criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains ZMYM3 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [3].